- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Hospice.
Displaying page 1 of 1.
EudraCT Number: 2013-005009-30 | Sponsor Protocol Number: | Start Date*: 2016-05-04 | ||||||||||||||||
Sponsor Name:Gloucestershire Hospitals NHS Foundation Trust and | ||||||||||||||||||
Full Title: An open label, randomised controlled feasibility pilot study to evaluate whether nasal fentanyl alone and in combination with buccal midazolam give better symptom control to dying patients when com... | ||||||||||||||||||
Medical condition: Adult hospice in-patients with terminal cancer who are thought to be in the last 1 - 2 weeks of life | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004831-23 | Sponsor Protocol Number: 2005-060 | Start Date*: 2006-01-09 |
Sponsor Name:Sankt Lukas Hospice | ||
Full Title: Effekten af "røde dråber" på åndenød hos terminale patienter med primær lungecancer eller lungemetastaser - et pilotprojekt | ||
Medical condition: Primær lungecancer og cancerpatienter med metastaser til lungerne | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004318-16 | Sponsor Protocol Number: DAS181-3-01 | Start Date*: 2020-01-16 | |||||||||||
Sponsor Name:Ansun Biopharma, Inc. | |||||||||||||
Full Title: A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects | |||||||||||||
Medical condition: Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002287-14 | Sponsor Protocol Number: Reutelen | Start Date*: 2016-12-23 | |||||||||||
Sponsor Name:Erasmus MC Cancer Institute | |||||||||||||
Full Title: Death rattle in the dying phase: is prophylactic treatment useful? | |||||||||||||
Medical condition: Death rattle in the dying phase | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004369-16 | Sponsor Protocol Number: MJ/LPGB/12/2006 | Start Date*: 2007-11-29 |
Sponsor Name:St Raphael's Hospice, Surrey | ||
Full Title: ''Evaluation of the efficacy of 'TRANS-DERMAL NITRATE' in reducing the severity of 'death-rattle' (i.e 'terminal lung secretions' ) in patients dying from end stage malignancy'' | ||
Medical condition: 'Death-rattle' (i.e 'terminal lung secretions') in adult patients dying from end-stage malignancy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-007053-51 | Sponsor Protocol Number: 003/APR06 | Start Date*: 2007-07-02 | ||||||||||||||||
Sponsor Name:Gloucestershire Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: Diamorphine or alfentanil for subcutaneous use in hospice in-patients | ||||||||||||||||||
Medical condition: Palliative Care | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022247-37 | Sponsor Protocol Number: BDP-GVHD-03 | Start Date*: 2010-11-24 | |||||||||||
Sponsor Name:Soligenix, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF ORBEC® (ORAL BECLOMETHASONE 17,21-DIPROPIONATE) IN CONJUNCTION WITH TEN DAYS OF HIGH-DOSE P... | |||||||||||||
Medical condition: Patients with acute gastrointestinal Graft Versus Host Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004360-44 | Sponsor Protocol Number: VAC034 | Start Date*: 2008-04-29 |
Sponsor Name:University of Oxford | ||
Full Title: Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAP | ||
Medical condition: Malaria | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-022413-26 | Sponsor Protocol Number: IDEAL-Study | Start Date*: 2011-07-29 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study) | |||||||||||||
Medical condition: Patients in late stage of HIV-infection, treatment naive or without ART for the last 6 month with an acute AIDS-defining illness, namely PCP or TE. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013929-42 | Sponsor Protocol Number: 39588146AHF2001 | Start Date*: 2010-07-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JNJ-39588146 in Subjects with Heart Failure | |||||||||||||
Medical condition: JNJ-39588146 is being developed for the treatment of heart failure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005731-41 | Sponsor Protocol Number: 3475-361 | Start Date*: 2016-10-31 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Car... | |||||||||||||
Medical condition: Advanced or Metastatic Urothelial Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002521-30 | Sponsor Protocol Number: HBI-8000-303 | Start Date*: 2022-03-07 | |||||||||||
Sponsor Name:HUYABIO International, LLC | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated w... | |||||||||||||
Medical condition: Metastatic or unresectable melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005872-29 | Sponsor Protocol Number: MORAb-003-004 | Start Date*: 2009-09-24 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Plati... | |||||||||||||
Medical condition: First relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) FR (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007690-21 | Sponsor Protocol Number: 42160443PAI2001 | Start Date*: 2009-10-02 | |||||||||||
Sponsor Name:Janssen Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Foll... | |||||||||||||
Medical condition: Subjects with inadequately controlled, moderate to severe, chronic, cancer-related pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Completed) PT (Completed) IT (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
